Katherine Stueland Sells 10,501 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,501 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $76.75, for a total value of $805,951.75. Following the completion of the transaction, the chief executive officer now directly owns 71,146 shares of the company’s stock, valued at approximately $5,460,455.50. This represents a 12.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total value of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total value of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total value of $1,628,651.84.
• On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The shares were sold at an average price of $66.60, for a total transaction of $143,456.40.

GeneDx Stock Down 2.1 %

Shares of NASDAQ:WGS opened at $75.30 on Friday. The firm has a market capitalization of $2.07 billion, a PE ratio of -24.21 and a beta of 2.03. GeneDx Holdings Corp. has a 1 year low of $2.11 and a 1 year high of $89.11. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The firm’s 50-day moving average is $72.11 and its two-hundred day moving average is $46.96.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. The firm had revenue of $76.90 million during the quarter, compared to analysts’ expectations of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The business’s quarterly revenue was up 44.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.82) earnings per share. Analysts predict that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Institutional Trading of GeneDx

Large investors have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in GeneDx in the second quarter valued at $2,362,000. Chartwell Investment Partners LLC purchased a new position in shares of GeneDx in the 3rd quarter valued at about $1,722,000. Lisanti Capital Growth LLC acquired a new position in shares of GeneDx during the third quarter worth about $1,554,000. Millennium Management LLC increased its stake in shares of GeneDx by 193.5% during the second quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock worth $8,140,000 after buying an additional 205,318 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in GeneDx by 304.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after acquiring an additional 110,666 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on WGS. Craig Hallum increased their price target on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. The Goldman Sachs Group lifted their price target on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, Wells Fargo & Company upped their price objective on shares of GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 30th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.33.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.